[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857-209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 63, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2020, "totalPay": 612000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 57, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2020, "totalPay": 589000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Piekos", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  DiVecchia", "title": "Senior Vice President of Operations & Human Resources", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.1, "open": 9.15, "dayLow": 8.858, "dayHigh": 9.2, "regularMarketPreviousClose": 9.1, "regularMarketOpen": 9.15, "regularMarketDayLow": 8.858, "regularMarketDayHigh": 9.2, "forwardPE": -2.195704, "volume": 57889, "regularMarketVolume": 57889, "averageVolume": 56757, "averageVolume10days": 38800, "averageDailyVolume10Day": 38800, "marketCap": 94033200, "fiftyTwoWeekLow": 2.96, "fiftyTwoWeekHigh": 24.39, "fiftyDayAverage": 6.8078, "twoHundredDayAverage": 7.06915, "currency": "USD", "enterpriseValue": 88056328, "floatShares": 5388927, "sharesOutstanding": 10221000, "sharesShort": 39524, "sharesShortPriorMonth": 28405, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0061000003, "heldPercentInsiders": 0.45064, "heldPercentInstitutions": 0.05308, "shortRatio": 0.71, "impliedSharesOutstanding": 10221000, "bookValue": 1.184, "priceToBook": 7.77027, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -35195000, "trailingEps": -6.96, "forwardEps": -4.19, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -2.49, "52WeekChange": 0.35693216, "SandP52WeekChange": 0.23099434, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.2, "targetHighPrice": 11.0, "targetLowPrice": 11.0, "targetMeanPrice": 11.0, "targetMedianPrice": 11.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 12894000, "totalCashPerShare": 1.262, "ebitda": -35363000, "totalDebt": 6917000, "quickRatio": 1.32, "currentRatio": 1.674, "debtToEquity": 60.819, "returnOnAssets": -0.89703006, "returnOnEquity": -3.46954, "freeCashflow": -16932500, "operatingCashflow": -32694000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]